For­mer Spark ex­ec to lead a gene ther­a­py up­start of his own; Big Phar­ma mar­ket­ing vet named CEO of Swiss biotech

→ Dave Green­wald’s days as act­ing CEO of Aper­tu­ra Gene Ther­a­py are over as Joseph La Barge steps in to lead the biotech, which just launched in April.

Peer Re­view had been won­der­ing about La Barge’s next land­ing spot since he left Spark at the end of 2021. In his eight-year stretch with the gene ther­a­py pi­o­neer, he be­gan as chief le­gal of­fi­cer and was lat­er pro­mot­ed to CBO in 2019, when Spark was sold to Roche for $4.3 bil­lion. Deer­field, where Green­wald is VP of busi­ness de­vel­op­ment, put up all the fi­nanc­ing for Aper­tu­ra’s $67 mil­lion Se­ries A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER